NCT06321679 Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
| NCT ID | NCT06321679 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Castration-resistant Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2020-07-03 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2020-07-03 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone. This is a monocentric, prospective observational study.
Eligibility Criteria
Inclusion Criteria: * Histological diagnosis of castration-resistant prostate cancer, * Single or multiple bone metastases, * Life expectancy of over 6 months, * No current active malignancy other than prostate cancer, * Provision of written informed consent. Exclusion Criteria: * Absolute contraindication to WB-MRI, CT or BS, * Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion), * Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.
Contact & Investigator
Giuseppe Petralia
PRINCIPAL INVESTIGATOR
European Institute of Oncology
Frequently Asked Questions
Who can join the NCT06321679 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Castration-resistant Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06321679 currently recruiting?
Yes, NCT06321679 is actively recruiting participants. Contact the research team at giuseppe.petralia@ieo.it for enrollment information.
Where is the NCT06321679 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06321679 clinical trial?
NCT06321679 is sponsored by European Institute of Oncology. The principal investigator is Giuseppe Petralia at European Institute of Oncology. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.